AllDocs -> cancers

PROFILE JANUARY 2005 22 SCHOLARLY ACTIVITIES SCHOLARLY ACTIVITIES New drug against liver cancer L iver cancer , also known as Hepatocellular Carcinoma or HCC is one of the five most common human cancers in the world and the second leading cause of cancer death in Hong Kong. A joint research team formed among our Department of Applied Biology and Chemical Technology, HKU’s Centre for the Study of Liver Disease and a commercial partner, has broken new ground in developing a drug to fight against liver cancer . The new drug is developed based on the mechanism of arginine depletion which is believed to be effective in inhibiting tumor growth in HCC without affecting the normal cells. Earlier, PolyU researchers have successfully produced a human recombinant arginase that has a prolonged half-life in the circulation to allow therapeutic ...

Web Immagini Gruppi Directory News altro » Ricerca avanzata Preferenze Cerca nel Web Cerca solo le pagine in Inglese Spiacenti, nessun contenuto associato a questo URL Web La ricerca di - cache:YRKKjo21V8AJ:www.cwru.edu/dental/web/cancer/cancer_cd2/clinical%20oncology/chapter17.pdf allintitle: liver cancer filetype:pdf OR filetype:doc OR filetype:ppt OR filetype:xls OR filetype:rtf - non ha prodotto risultati in nessun documento. Suggerimenti: Assicurarsi che tutte le parole siano state digitate correttamente. Provare con parole chiave diverse. Provare con parole chiave più generiche. Provare con ...

1 Why Eradicating Hepatitis B and Liver Cancer should be a National Priority in China ? - Professor Samuel So Asian Liver Center at Stanford University (Presented at the China National Conference on Hepatitis Prevention and Control, Hangzhou, China, April 26-29, 2004) If you judge by the focus of international and media reports, you would think that HIV/AIDS, SARS, and the avian flu, are the major health problems facing China today. An estimated 17,000 people died of HIV in 1999, and by 2003, approximately a million people in China is living with HIV. In response to this rising threat, a national plan for AIDS prevention and control (1998-2010) has been developed and adopted. During the SARS outbreak in 2003, 5327 people in China were infected and 349 died of SARS. To date, there has been no report of death from avian flu in China. In contrast, hepatitis B which poses ...

1 Why Eradicating Hepatitis B and Liver Cancer should be a National Priority in China ? - If you judge by the focus of international and media reports, you would think that HIV/AIDS, SARS, and the avian flu, are the major health problems facing China today. An estimated 17,000 people died of HIV in 1999, and by 2003, approximately a million people in China is living with HIV. In response to this rising threat, a national plan for AIDS prevention and control (1998-2010) has been developed and adopted. During the SARS outbreak in 2003, 5327 people in China were infected and 349 died of SARS. To date, there has been no report of death from avian flu in China. In contrast, hepatitis B which poses the greatest threat to the health of the nation has received little attention. One in ten Chinese (130 million) has chronic hepatitis B. In China, every 60 seconds, a person die from liver cancer ...

1/3 Press Information Screening for Liver Cancer in Patients with Chronic Viral Infection Effectively Improves Chance of Treatment and Survival Background It is estimated that 300 to 400 million people have chronic hepatitis B infection. Of these, 75% carriers are Asians. Importantly, 25 to 40% will develop cirrhosis or liver cancer . In Hong Kong, there were 1,576 new cases of liver cancer with 1,381 deaths in 2002 according to the Hong Kong Cancer Registry. Liver cancer ranks the second and ninth most common cancer in male and female respectively. The prognosis of liver cancer is dismal because most of the patients with liver cancer do not have symptoms. By the time of occurrence of symptoms, it is usually at the late stage of the disease. It is therefore important to diagnose liver cancer at early stage in order to improve chance of receiving treatment and survival. ...

Jun. 2005, Volume 2, No.6 (Serial No.7) Journal of US -China Medical Science, ISSN 1548-6648,USA 16 460 Cases of Radiotherapy for Primary Massive Liver Cancer * Zuoshen Zheng ** , Yuhe Zou , Jian Rao , Huazhu Lv , Yuehai Zheng , Xuezhong Chen Abstract: Objective To summarize the improvement of technological by radiotherapy with moving split fields radiation (MSFR) of the whole liver and diminution field technology and split course and to explore the significance by radiotherapy for primary massive Liver Cancer (PLC). Methods 460 patients with PLC underwent in our hospital between 1987 and 2001 were carried out for retrospective analysis. There were 386 male and 74 female cases of these patients, and the average age was 46.2 years. The tumor size of 245 patients is 1015 cm. The others is 1521 cm. There were three groups defined by the irradiation doses: (1) ...

A205 : Liver cancer tissues - Cholangiocarcinoma For research use only (formalin fixed) Specifications: •No. of cases: 46 •Tissue type: Liver cancer tissues – Chalangicarcinoma •No. of spots: 2 spots from each cancer case (92 spots) 4 non-neoplastic spots (4 spots) •Total spots: 96 •Corresponding normal tissues with cancers: No •Diameter: 1.0 mm Documents: •Product specification: layout, summary of tissue spots •H&E stained images •Detailed pathological information Layout: Page 2 A205 : Liver cancer tissues - Cholangiocarcinoma For research use only (formalin fixed) Summary of tissue spot No Sex Age KeyWord Grade TNM Stage 1 1, 2 f 73 Cholangio ca. G1 T1N0M0 (I) 2 3, 4 f 69 ...

PO Box 2345, Beijing 100023, China World J Gastroenterol 2004;10(15):2201-2204 Fax: +86-10-85381893 World Journal of Gastroenterology E-mail: wjg@wjgnet.com www.wjgnet.com Copyright © 2004 by The WJG Press ISSN 1007-9327 • LIVER CANCER • Analysis of clinical effect of high-intensity focused ultrasound on liver cancer Chuan-Xing Li, Guo-Liang Xu, Zhen-You Jiang, Jian-Jun Li, Guang-Yu Luo, Hong-Bo Shan, Rong Zhang, Yin Li Chuan-Xing Li, Guo-Liang Xu, Jian-Jun Li, Guang-Yu Luo, Hong- Bo Shan, Rong Zhang, Yin Li, Department of HIFU, Cancer Center, Sun Yat-sen University, Guangzhou 510060, Guangdong Province, China Zhen-You Jiang, Medical College, Jinan University, Guangzhou 510632, Guangdong Province, China Correspondence to: Chuan-Xing Li, Department of HIFU, Cancer Center, Sun Yat-sen University, Guangzhou 510060, Guangdong Province, ...

Contact: Diane Shnitzler or Emily Oehler (703) 691-1805 November 28-Dec 1: Emily Oehler, (703) 801-7790 Diane Shnitzler, (571) 276-8480 Embargoed for Release, November 28, 2005 Week-Long Symposium on Minimally Invasive Cancer Treatments for Liver , Kidney, Bone and Lung, and Emerging Research Society of Interventional Radiology Foundation and RSNA Convene Multi-Disciplinary Oncology Meeting in the Clinical and Basic Science of Interventional Oncology Chicago, IL (November 28, 2005) – Clinicians and basic scientists from academia, private practice, government and industry come together today for a week-long multi-disciplinary symposium in interventional oncology, a rapidly growing area of medicine involving minimally invasive interventional radiology treatments for cancer . The first two days of the meeting focus on treatments for liver , kidney, bone ...

Breakthrough TM B R E A K T H R O U G H M E D I C I N E — E X C E P T I O N A L C A R E F O R A H E A LT H Y C O M M U N I T Y W I N T E R 2 0 0 5 Surviving acute liver failure Laser surgery zaps throat cancer Living with lung cancer Minimal approach relieves back pain Fixing a broken wrist the modern way Second chance after heart attack Page 2 Even though she was feeling under the weather, Mari-jo Fraser found the en- ergy to play nine innings of baseball – it took a lot to keep her from playing her favorite sport. The next day, Fraser wasn’t feeling any better, but she decided to drive to Tacoma to watch her husband, Sean, play. “Before we left, I noticed that my eyes were look- ing yellow,” she recalls. Fraser had gone to the doctor the day before her game, suspecting she was preg- nant, or perhaps ...

81 ©2005, Institute of Oncology Sremska Kamenica, Serbia and Montenegro Archive of Oncology 2005;13 Suppl 1:81. Zoran PETROVI Dino TARABAR Nebojpa MANOJLOVI Rajko DODER DEPARTMENT OF GASTROINTESTINAL ONCOLOGY, CLINIC FOR GASTROENTEROLOGY, MMA, BELGRADE, SERBIA AND MONTENEGRO EGFR expression in liver metastases in patients with colorectal cancer EGFR positive primary tumor and response to systemic chemotherapy and targeted therapy Conference abstract UDC: 616.36-006:616.348-006:616.351-006:615-085 KEYWORDS: Receptor,Epidermal Growth Factor; ColorectalNeoplasms; Neoplasm Metastasis –ore ARGIROVI CLINIC OF UROLOGY, DIVISION OF UROLOGIC CHEMOTHERAPY, CLINICAL CENTER OF SERBIA, BELGRADE, SERBIA AND MONTENEGRO Does retroperitoneal lymphadenectomy represent the best treatment option in patients with clinical stage A of nonseminomatous testicular ...

• LIVER CANCER • Anti-hepatoma effect of arsenic trioxide on experimental liver cancer induced by 2-acetamidofluorene in rats Bing Tan, Jie-Fei Huang, Qun Wei, Hong Zhang, Run-Zhou Ni ELSEVIER PO Box 2345, Beijing 100023, China World J Gastroenterol 2005;11(38):5938-5943 www.wjgnet.com World Journal of Gastroenterology ISSN 1007-9327 wjg@wjgnet.com © 2005 The WJG Press and Elsevier Inc. All rights reserved. Bing Tan, Jie-Fei Huang, Qun Wei, Hong Zhang, Run-Zhou Ni, Department of Digestive Medicine, Affiliated Hospital of Nantong Medical College, Nantong 226001, Jiangsu Province, China Co-first-authors: Bing Tan Correspondence to: Dr. Jie-Fei Huang, Department of Digestive Medicine, Affiliated Hospital of Nantong Medical College, Nantong 226001, Jiangsu Province, China Telephone: +86-513-5806629 Received: 2004-06-08 Accepted: ...

• LIVER CANCER • Inhibitory effects of N-(4-hydrophenyl) retinamide on liver cancer and malignant melanoma cells Xing-Zhong Wu, Li Zhang, Bi-Zhi Shi, Ping Hu ELSEVIER PO Box 2345, Beijing 100023, China World J Gastroenterol 2005;11(37):5763-5769 www.wjgnet.com World Journal of Gastroenterology ISSN 1007-9327 wjg@wjgnet.com © 2005 The WJG Press and Elsevier Inc. All rights reserved. Xing-Zhong Wu, Li Zhang, Bi-Zhi Shi, Ping Hu, Department of Biochemistry and Molecular Biology, Shanghai Medical College, Fudan University, Shanghai 200032, China Supported by the National Natural Science Foundation of China, No. 30070183 and 30470398 Correspondence to: Professor Xing-Zhong Wu, MD, PhD, Department of Biochemistry and Molecular Biology, Shanghai Medical College, Fudan University, Shanghai 200032, China. xz_wu@shmu.edu.cn ...

26 Dartmouth Medicine ternal beam radiation. The Y-90 decays over 2.7 days into non-ra- dioactive zirconium, and the tiny bits of by-then inert glass stay in the liver , causing no problems. Patients who have had Therasphere have suffered mini- mal side effects, and their tumors have decreased substantially in size. Zaki says it is a very good al- ternative to the traditional treat- ment, transarterial chemoem- bolization (TACE). TACE com- bines anti- cancer drug therapy to shrink the tumor with emboliz- ing, or blocking, the hepatic artery that feeds the tumor. However, TACE requires a hos- pital stay of two to five days and can cause more damage to sur- rounding tissue than Thera- sphere. In addition, most pa- tients suffer post-embolization syndrome—a reaction to blood being cut off to a solid organ—as well as nausea, abdominal pain, ...

SCIENCE RADIATION ONCOLOGY 106 MEDICAL SOLUTIONS OCTOBER 2005 Siemens Imaging Solutions Facilitate New Radiation Therapy Approach to Liver Cancer Using yttrium-90 microspheres is a new intraarterial therapy that uses beta-irradiating microspheres directly delivered to the tumor. The procedure demands the use of technologically advanced imaging equipment. A case study. By Andrew S. Kennedy, M.D., FACRO, Wake Radiology Oncology, Cary, NC Most patients with colorectal, breast, lung, hepatocellular, and pancreatic cancers are at risk to recur from metastatic disease in the liver after potentially curative treatment. When the liver does harbor metastatic or primary cancer , treatment options and ultimately their chances of survival rapidly decline. That is in part because the liver is at once amazing in its ability to grow larger (hypertrophy) ...

ASX/MEDIA RELEASE 31 October 2005 BrachySil™ Phase IIb Clinical Trials for Liver Cancer Commence Following Approval by HSA First patient in multi-centre dose-profiling study receives treatment in Singapore General Hospital after approval by the Health Sciences Authority Global bio-nanotech company pSivida Limited (ASX:PSD, NASDAQ:PSDV, XETRA:PSI) is very pleased to announce that Phase IIb clinical trials have commenced with BrachySil™ (32-P BioSilicon™) as a potential new brachytherapy treatment for inoperable primary liver cancer (hepatocellular carcinoma, HCC). The first patient has successfully received treatment at Singapore General Hospital (“SGH”) using a new fine-gauge needle, multi-injection device which will enable for the first time, larger and also multiple tumors to be treated. A total of 50 patients will be entered into this multi-centre trial, which will be conducted ...

• LIVER CANCER • Hepatic artery infusion of antisense oligodeoxynucleotide and lipiodol mixture transfect liver cancer in rats Han-Ping Wu, Gan-Sheng Feng, Yuan Tian ELSEVIER PO Box 2345, Beijing 100023, China World J Gastroenterol 2005;11(16):2408-2412 www.wjgnet.com World Journal of Gastroenterology ISSN 1007-9327 wjg@wjgnet.com © 2005 The WJG Press and Elsevier Inc. All rights reserved. Han-Ping Wu, Gan-Sheng Feng, Department of Interventional Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China Yuan Tian, Laboratory of General Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China Correspondence to: Dr. Han-Ping Wu, Department of Interventional Radiology, Union Hospital, ...

P.1 Novel Treatment for Primary Liver Cancer Joint Universities and Biotechnological Industry in Drug Development Dr Tung-ping Poon, Ronnie, Assistant Dean (Research), Faculty of Medicine, The University of Hong Kong Dr Ning-man Cheng, Paul, Adjunct Associate Professor, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University Dr Yun-chung Leung, Thomas, Lecturer, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University Dr Wai-hung Lo, Thomas, Lecturer, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University Hepatocellular carcinoma (HCC) is one of the five most common human cancers worldwide. It is the second leading cause of cancer death in Hong Kong. About 1,500 new patients are identified every year. According ...

Web Immagini Gruppi Directory News altro » Ricerca avanzata Preferenze Cerca nel Web Cerca solo le pagine in Inglese Spiacenti, nessun contenuto associato a questo URL Web La ricerca di - cache:7IU8KaIL8oAJ:sci.tech-archive.net/pdf/Archive/sci.med.diseases.cancer/2004-10/0046.pdf allintitle: liver cancer filetype:pdf OR filetype:doc OR filetype:ppt OR filetype:xls OR filetype:rtf - non ha prodotto risultati in nessun documento. Suggerimenti: Assicurarsi che tutte le parole siano state digitate correttamente. Provare con parole chiave diverse. Provare con parole chiave più generiche. Provare con ...

What You Need To Know About Liver Cancer NATIONAL INSTITUTES OF HEALTH National Cancer Institute ™ What You Need To Know About Index Page 2 This booklet is about liver cancer . The Cancer Information Service can help you learn more about this disease. The staff can talk with you in English or Spanish. The number is 1–800–4– CANCER (1–800–422–6237).The number for deaf and hard of hearing callers with TTY equipment is 1–800–332–8615. The call is free. Este folleto es acerca del cáncer del higado. Llame al Servicio de Información sobre el Cáncer para saber más sobre esta enfermedad. Este servicio tiene personal que habla español. El número a llamar es el 1–800–4– CANCER (1–800–422–6237). Personas con problemas de ...

N N E E W W S S 4 February 2004 Revolutionary liver cancer treatment to be showcased at Medway The Medway NHS Trust is hosting a ground breaking clinical workshop on 17 February 2004 at the Medway Maritime Hospital, Gillingham which will include two live demonstrations of an exciting new procedure for the diagnosis and treatment of liver cancer . The internationally respected specialist, Professor R Lencioni of Pisa Hospital, Italy, will perform this procedure, which is based on Contrast Enhanced Ultrasound (CEUS) and Radiofrequency Ablation (RFA). The thrust of this new advance is local deposition of thermal energy directly to the tumour cells, which heats and destroys the cancerous tissue. Electrodes shaped like needles are inserted into the liver . This is achieved without making cuts and Ultrasound images ...